Pitolisant-oxalate-Tiprolisant-oxalate-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPitolisant oxalateCat. No.: HY-12199ACAS No.: 362665-57-4Synonyms: Tiprolisant oxalate分式: CHClNO分量: 385.88作靶點: Histamine Receptor作通路: GPCR/G Protein; Immunology/Inflammation; NeuronalSignaling儲存式: Please store the product under

2、the recommended conditions inthe COA.溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (129.57 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.5915 mL 12.9574 mL 25.9148 mL5 mM 0.5183 mL 2.5915 mL 5.1830 mL10 mM 0.2591 mL 1.2957 mL 2.5915 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物

3、和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.48 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.48 mM); C

4、lear solution3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.48 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Pitolisant草酸鹽(BF2.649)新型的重 組H3受體選擇性反向激動劑，Ki為0.16 nM。IC50 & Target Ki: 0.16 nM (H3 receptor) 1EC50: 1.5 nM (H3 receptor) 1體外研究 On the

5、stimulation of guanosine 5-O-(3-35Sthio)triphosphate binding to this receptor, Pitolisant (BF2.649)behaves as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50value of 1.5 nM and an intrinsic activity 50% higher than that of ciproxifan. Pitolisant displaces12

6、5Iiodoproxyfan binding from mouse brain cortical membranes with an IC50 value of 26.44.5 nM. Takinginto account the Kd value of the radioligand (1619 pM), the deduced Ki value for Pitolisant is 141 nM.Pitolisant displaces 125Iiodoproxyfan binding from membranes of rat glioma C6 cells stably expressi

7、ng thehuman H3 receptor with an IC50 value of 4.20.2 nM. Taking into account the Kd value of the radioligand(504 pM), the deduced Ki value for Pitolisant is 2.70.5 nM. Pitolisant progressively reverses this responsewith a Hill coefficient close to unity and an IC50 value of 33068 nM, leading to a Ki

8、 value of 174 nM.Pitolisant elicits a dose-dependent decrease of the basal-specific 35SGTPS binding to membranes with amaximal effect corresponding to 751% of the basal-specific binding and an EC50 value of 1.50.1 nM 1.體內(nèi)研究 The administration of Pitolisantat a single dose of 10 mg/kg 30 min before a

9、 single dose of Olanzapine (2mg/kg b.w.) also significantly affects immobility time in the FST. Subsequent administration of theaforementioned drug sequence in mice statistically significantly increases the duration of immobility incomparison to the time determined in the control group in the FST. I

10、t decreased locomotor activity as well. Incontrast, the results obtained in subchronic treatment after fifteen administrations of both drugs (Pitolisant 10mg/kg b.w., and after 30 min Olanzapine 2 mg/kg b.w., and again after 4 h Olanzapine 2 mg/kg b.w.) showthat the administration of Pitolisant foll

11、owed by that of Olanzapine equalized the locomotor activity in mice; incomparison to the level of motility in the control group, to which only Pitolisant is administered. Moreimportantly, this combination of drugs significantly reduces immobility time to the level obtained in the controlgroup in the

12、 forced swim test in mice one-way ANOVA; F (3,20)=4.226,P=0.0181 2. Rats given Pitolisant(10 mg/kg) during the conditioning phase stayed 50294 s on the paired texture, a value not statisticallydifferent from that of controls, indicating that Pitolisant did not support place preference 3.PROTOCOLKina

13、se Assay 1 35SGTPS binding assays are performed. CHO-K1 cells stably expressing the human H3 receptor (400fmol/mg protein) are homogenized in ice-cold buffer (50 mM Tris/HCl, pH 7.4). Homogenates are centrifugedtwice (20,000g for 10 min at 4C), and the final pellet is resuspended in 50 volumes of bu

14、ffer. Membranes(550 g of protein) are pretreated with adenosine deaminase (1 U/mL) and incubated for 60 min at 25C with0.1 nM 35SGTPS and the drugs to be tested in a final volume of 1 mL of assay buffer (50 mM Tris/HCl, 50mM NaCl, 5 mM MgCl2, 10 M GDP, and 0.02% bovine serum albumin, pH 7.4). The no

15、nspecific binding isdetermined using 10 M nonradioactive GTPS. Incubations are stopped by rapid filtration under vacuumthrough GF/B glass fiber filters. After washing with ice-cold water, the radioactivity trapped on filters is2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEcounted by liquid scinti

16、llation spectrometry. A similar assay is used to assess competitive antagonism. Inbrief, membranes (10 g of protein) of HEK-293 cells stably expressing the human H3 receptor (600fmol/mg protein) are preincubated in presence of Pitolisant in the buffer (50 mM Tris/HCl, pH 7.4, 10 mMMgCl2, 100 mM NaCl

17、, and 10 M GDP) in a 96-well microplate under gentle agitation at room temperature(19-20C) for 30 min before the addition of 0.1 nM 35SGTPS (final volume 200 L). The nonspecificbinding is determined using a 10 M concentration of nonradioactive GTPS. After 30 min, incubationsperformed in triplicate a

18、re stopped by rapid filtration under vacuum on a Multiscreen MAFCOB50 microplate.Radioactivity trapped on filters is counted by liquid scintillation spectrometry 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 23 Adult fema

19、le Albino Swiss mice weighing 20-22 g are used in the study. Olanzapine or Pitolisant aresuspended in 1 % Tween 80. The compounds or vehicle are administered intraperitoneally (i.p.) 30 min priorto the acute experiment. In the Pitolisant+Olanzapine group, Pitolisant is administered 15 min beforeOlan

20、zapine. Subchronic treatment is done at about 9:00 am (0.2 mL Tween to control group, Pitolisant-10mg/kg b.w. to Pitolisant group, Olanzapine-2 mg/kg b.w. to Olanzapine group, Pitolisant-10 mg/kg b.w. andOlanzapine after 15 min-2 mg/kg b.w. to Pitolisant+Olanzapine group) and at about 1:00 pm (Olanz

21、apinegroup and Pitolisant+Olanzapine group).Rats 3Male Wistar rats (220-300 g) receive vehicle (methylcellulose 1%, p.o.), Pitolisant (10 mg/kg, p.o.) or D-amphetamine (2.5 mg/kg, i.p. in saline). Ninety minutes later, they are killed by decapitation and nucleusaccumbens are dissected out, weighed,

22、frozen in liquid nitrogen and stored at -80C. Tissues arehomogenized in 1 mL of a 0.4 N perchloric acid/2.7 mM EDTA solution. After centrifugation (8000 rpm, 20min, 4C), supernatants are analysed by HPLC coupled to electrochemical detection. Tissue concentrationsof dopamine (DA), dihydroxyphenyl acetic acid (DOPAC) and homovanillic acid (HVA) are determined andthe corresponding ratios (DOPAC/DA, HVA/DA) are calculated.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Ligneau X, et al. BF2.649 1-3-3-(4-Chlorophenyl